Caroline S. De Freitas

Rio De Janeiro, RJ 21040361, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Newly Proposed Dose of Daclatasvir to Prevent Lethal SARS-CoV-2 Infection in Human Transgenic ACE-2 Mice.

Newly Proposed Dose of Daclatasvir to Prevent Lethal SARS-CoV-2 Infection in Human Transgenic ACE-2 Mice.

Journal: Viruses

Published: October 14, 2024

Extracellular vesicles from primary human macrophages stimulated with VIP or PACAP mediate anti-SARS-CoV-2 activities in monocytes through NF-κB signaling pathway.

Extracellular vesicles from primary human macrophages stimulated with VIP or PACAP mediate anti-SARS-CoV-2 activities in monocytes through NF-κB signaling pathway.

Journal: Microbes and infection

Published: January 30, 2024

Severe influenza infection is associated with inflammatory programmed cell death in infected macrophages.

Severe influenza infection is associated with inflammatory programmed cell death in infected macrophages.

Journal: Frontiers in cellular and infection microbiology

Published: October 11, 2022

Agathisflavone, a natural biflavonoid that inhibits SARS-CoV-2 replication by targeting its proteases.

Agathisflavone, a natural biflavonoid that inhibits SARS-CoV-2 replication by targeting its proteases.

Journal: International journal of biological macromolecules

Published: August 15, 2022

Simvastatin Downregulates the SARS-CoV-2-Induced Inflammatory Response and Impairs Viral Infection Through Disruption of Lipid Rafts.

Simvastatin Downregulates the SARS-CoV-2-Induced Inflammatory Response and Impairs Viral Infection Through Disruption of Lipid Rafts.

Journal: Frontiers in immunology

Published: November 22, 2021

VIP plasma levels associate with survival in severe COVID-19 patients, correlating with protective effects in SARS-CoV-2-infected cells.

VIP plasma levels associate with survival in severe COVID-19 patients, correlating with protective effects in SARS-CoV-2-infected cells.

Journal: Journal of leukocyte biology

Published: November 18, 2021

Correction: SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes.

Correction: SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes.

Journal: Cell death discovery

Published: May 20, 2021

SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes.

SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes.

Journal: Cell death discovery

Published: December 07, 2020

Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators.

Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediators.

Journal: PLoS pathogens

Published: November 04, 2020

In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19.

In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19.

Journal: The Journal of antimicrobial chemotherapy

Published: October 10, 2020

Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.

Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.

Journal: Antimicrobial agents and chemotherapy

Published: April 28, 2020

Neuraminidase from Influenza A and B Viruses is Susceptible to the Compound 4-(4-Phenyl-1H-1,2,3-Triazol-1-yl)-2,2,6,6-Tetramethylpiperidine-1- Oxyl.

Neuraminidase from Influenza A and B Viruses is Susceptible to the Compound 4-(4-Phenyl-1H-1,2,3-Triazol-1-yl)-2,2,6,6-Tetramethylpiperidine-1- Oxyl.

Journal: Current topics in medicinal chemistry

Published: August 21, 2019

Showing 1-12 of 21

Last Updated: 09/26/2026